Tele-Rehabilitation Intervention in Community-Based Healthcare for Patients With Osteoporosis (DHEAL-COM-OP)
DHEAL-COM-OP
1 other identifier
interventional
40
1 country
1
Brief Summary
The DHEAL-COM-OP study is characterized as a feasibility study. The general objective is to evaluate the improvement in the physical performance of patients with osteoporosis detected through the Performance-Oriented Mobility Assessment (POMA) scale, following a rehabilitation intervention integrated with the BTS TELEREHAB technology.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2025
CompletedFirst Posted
Study publicly available on registry
May 22, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 30, 2026
May 30, 2025
May 1, 2025
9 months
May 14, 2025
May 23, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Improvement in physical performance
The physical performance, in terms of balance and gait ability, will be detected through the Tinetti Performance Oriented Mobility Assessment (POMA) scale. The maximum possible score is 28 points. The total POMA score provides an indication of an individual's fall risk: * 25-28 points: Indicates a low risk of falls * 19-24 points: Indicates a medium or moderate risk of falls * Less than 19 points (\< 19): Indicates a high risk of falls The improvement is assessed in an increase in the POMA score of at least 3 points.
At baseline and 12 weeks later
Secondary Outcomes (3)
Improvement in physical function
At baseline and 12 weeks later
Improvement in quality of life
At baseline and 12 weeks later
Improvement in mobility
At baseline and 12 weeks later
Study Arms (2)
Intervention arm
EXPERIMENTALOlder patients with osteoporosis
Usual care
SHAM COMPARATOROlder patients with osteoporosis
Interventions
Patients will receive a personalised home tele-rehabilitation exercise program consisting of 3 sessions per week for a duration of 12 weeks. BTS TELEREHAB is a platform that allows the delivery of remote rehabilitation services. The patient is given the system to take home, where they will connect the small Brain PC, that is the computer unit of the BTS TELEREHAB solution, to their television. During motor rehabilitation sessions, the patient wears a special inertial sensor, the G-Sensor device, that measures movements in real-time, allowing the clinician to remotely monitor the correct execution of the exercises. In addition to the proposed therapeutic exercises, functional assessment tests are also included for patient follow-up. The presence of the inertial sensor supports the clinician in verifying the correct execution of the motor task and in the precise quantification of joint mobility.
Participants will receive a booklet containing information and activities on well- being. They will be invited to do whatever they wish with the information booklet and the proposed exercises.
Eligibility Criteria
You may qualify if:
- Patients with a positive MOC for osteoporosis without a history of major fractures (femur and vertebrae);
- Functional Ambulation Category (FAC) score ≥ 3;
- Stability of drug treatment for at least 1 month;
- Maintaining an upright position independently \> 30";
- Mini-Mental State Examination (MMSE) ≥ 24;
- Geriatric depression scale (GDS) \< 2;
You may not qualify if:
- Myocardial infarction or stroke within 6 months;
- Painful arthritis, spinal stenosis, amputation, painful foot lesions, or neuropathy that limits balance and mobility;
- Uncontrolled hypertension
- Metastatic cancer or immunosuppressive therapy;
- Significant visual or hearing impairment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCCS INRCA Hospital
Ancona, 60127, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Giovanni Renato Riccardi, MD
IRCCS INRCA, Ancona, Italy
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2025
First Posted
May 22, 2025
Study Start
September 1, 2025
Primary Completion (Estimated)
May 30, 2026
Study Completion (Estimated)
May 30, 2026
Last Updated
May 30, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share